Showing 561 - 580 results of 2,564 for search '(( significant decrease decrease ) OR ( significant ((non decrease) OR (a decrease)) ))~', query time: 0.61s Refine Results
  1. 561

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Background<p>Atopic Dermatitis (AD), a chronic inflammatory skin disease characterized by pruritus, dryness, redness, edema, scratching, and lichenification, ranks as the leading cause of non-fatal skin disease burden globally. …”
  2. 562

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Background<p>Atopic Dermatitis (AD), a chronic inflammatory skin disease characterized by pruritus, dryness, redness, edema, scratching, and lichenification, ranks as the leading cause of non-fatal skin disease burden globally. …”
  3. 563
  4. 564

    Flow chart of the literature search. by Xiaojuan Yang (794374)

    Published 2025
    “…<div><p>Background and aim</p><p>Post-burn scarring is a prevalent condition, and the existing non-surgical treatments exhibit varying degrees of efficacy. …”
  5. 565

    Funnel plot for scar thickness. by Xiaojuan Yang (794374)

    Published 2025
    “…<div><p>Background and aim</p><p>Post-burn scarring is a prevalent condition, and the existing non-surgical treatments exhibit varying degrees of efficacy. …”
  6. 566

    Network plot for VSS score. by Xiaojuan Yang (794374)

    Published 2025
    “…<div><p>Background and aim</p><p>Post-burn scarring is a prevalent condition, and the existing non-surgical treatments exhibit varying degrees of efficacy. …”
  7. 567

    Network plot for scar thickness. by Xiaojuan Yang (794374)

    Published 2025
    “…<div><p>Background and aim</p><p>Post-burn scarring is a prevalent condition, and the existing non-surgical treatments exhibit varying degrees of efficacy. …”
  8. 568

    Funnel plot for VSS score. by Xiaojuan Yang (794374)

    Published 2025
    “…<div><p>Background and aim</p><p>Post-burn scarring is a prevalent condition, and the existing non-surgical treatments exhibit varying degrees of efficacy. …”
  9. 569

    Characteristics of the included trials (n = 17). by Xiaojuan Yang (794374)

    Published 2025
    “…<div><p>Background and aim</p><p>Post-burn scarring is a prevalent condition, and the existing non-surgical treatments exhibit varying degrees of efficacy. …”
  10. 570

    Risk of bias graph. by Xiaojuan Yang (794374)

    Published 2025
    “…<div><p>Background and aim</p><p>Post-burn scarring is a prevalent condition, and the existing non-surgical treatments exhibit varying degrees of efficacy. …”
  11. 571

    Network plot for VAS score. by Xiaojuan Yang (794374)

    Published 2025
    “…<div><p>Background and aim</p><p>Post-burn scarring is a prevalent condition, and the existing non-surgical treatments exhibit varying degrees of efficacy. …”
  12. 572

    Funnel plot for VAS score. by Xiaojuan Yang (794374)

    Published 2025
    “…<div><p>Background and aim</p><p>Post-burn scarring is a prevalent condition, and the existing non-surgical treatments exhibit varying degrees of efficacy. …”
  13. 573

    Vertebral cancellous tissueμCT parameters are not significantly affected by aging from 16 to 21 weeks, housing type, or microgravity. by Rukmani Cahill (20939813)

    Published 2025
    “…Data shown are the mean ±  standard deviation with a scatter plot (ns: non-significant). (G) μCT volumetric reconstructions of a representative sample from each group show a slight decrease in bone parameters from FL mice, which are not deemed significant by statistical testing.…”
  14. 574

    Mice in the NTC and MBC-005 treatment groups were evaluated for bioluminescent signaling at 6-, 13-, and 21-days after tumor inoculation. by Bryan S. Margulies (21492667)

    Published 2025
    “…<p>(A) Malthusian non-linear regression analysis demonstrated that the whole-body bioluminescent signal was significantly different between the different treatment groups (p < 0.0001). …”
  15. 575
  16. 576

    The MTT assay and the LDH assay were used to assess the effects of the hydrogel component of MBC-005 on tumor cell number and cell death. by Bryan S. Margulies (21492667)

    Published 2025
    “…<p>MC3T3-E1 cells (MC3) were used as a non-tumor cell control. (A) There was no statistically significant difference (NS) in MTT values between the MC3 cell cultures at 24- and 72-hours. …”
  17. 577

    Cox proportional hazard ratios. by Bryan S. Margulies (21492667)

    Published 2025
    “…Intratumoral administration of MBC-005 increased survival 3.9-fold in mice and significantly decreased tumor volume 4-fold. While many cytotoxic therapies increase p21 expression as a response to DNA damage, MBC-005 increased p21 expression independent cytotoxic DNA damage. …”
  18. 578

    Bioluminescent Doubling Time. by Bryan S. Margulies (21492667)

    Published 2025
    “…Intratumoral administration of MBC-005 increased survival 3.9-fold in mice and significantly decreased tumor volume 4-fold. While many cytotoxic therapies increase p21 expression as a response to DNA damage, MBC-005 increased p21 expression independent cytotoxic DNA damage. …”
  19. 579

    Study Design. by Bryan S. Margulies (21492667)

    Published 2025
    “…Intratumoral administration of MBC-005 increased survival 3.9-fold in mice and significantly decreased tumor volume 4-fold. While many cytotoxic therapies increase p21 expression as a response to DNA damage, MBC-005 increased p21 expression independent cytotoxic DNA damage. …”
  20. 580